medEctoin® in Dermatology
Making people feel comfortable in their own skin: Join our mission for radiant, healthy skin and increased quality of life – clinically proven, without any side effects.
Verified Efficacy
Boosting Skin Cells
medEctoin® improves cells in many ways, making them more resilient and healthier and providing benefits to both healthy and inflamed skin. The following selected official claims are clinically substantiated by numerous studies:
-
Significant Reduction of Itching, Redness and Scratching.
By calming inflammation and hydrating the skin, medEctoin® helps alleviate the intense itching that accompanies atopic dermatitis, reducing the urge to scratch and preventing further skin damage.
-
Significant Reduction of Scaling, Roughness and Hardening of the Skin.
Psoriasis often leads to dry, scaly patches of skin. medEctoin® binds water molecules, keeping the skin hydrated and preventing further drying and cracking, which helps smooth and soften the skin.
-
Reduction of Inflammatory Processes.
medEctoin® has strong inflammation-reducing properties, which help reduce the redness, swelling, and irritation associated with atopic dermatitis. It soothes inflamed skin, providing relief from discomfort.
-
Intense Moisturization of the Skin and Prevention From Further Dehydration.
medEctoin® is a powerful moisturizer that binds water molecules and locks in moisture. This keeps the skin hydrated for longer periods, reducing the dryness and flakiness common in atopic dermatitis. A study with 35 patients proves: A single application increases the skin's water content by up to 61%.
(Prof. Dr. med. T. Dirschka; unpublished study btph-043-2019_EHK02; 35 patients; diagnosed atopic dermatitis for ≥ 6 months; in asymptomatic stage; 8 days of treatment.)
-
medEctoin® + Cortisone is Up to 80 % More Effective Than Cortisone Alone.
The moisturizing and protecting properties of medEctoin® complement the potent anti-inflammatory action of corticosteroids. The combination of medEctoin® with other topical corticosteroids is up to 80 % more effective than treatment with corticosteroids alone.
(Kauth M, Trusova OV.; Topical Ectoine Application in Children and Adults to Treat Inflammatory Diseases Associated with an Impaired Skin Barrier: A Systematic Review; Dermatol Ther (Heidelb). 2022;12:295-313)
Clinically Proven:
medEctoin® in Dermatology
medEctoin® creams combat inflammatory skin conditions such as psoriasis and eczema. This is not just the testimony of consumers; scientists from around the world have been able to confirm numerous clinical effects in studies.
Reduces Atopic Dermatitis Symptoms by 50%
Participants
65 patients, mild to moderate AD, 18-65 years.
Duration
28 days.
Method
After 7 and 28 days, treated skin areas were assessed by modified,
objective local SCORAD, IGA and the patients’ judgment of efficacy.
Treatment
Patients applied medEctoin® Dermatitis Cream 7% and a nonsteroidal
anti-inflammatory cream on two symmetrical lesions twice daily.
Ask an Expert
Prof. Dr. Ralph Mösges was the chairman of the International Standardization Committee for the Objective Assessment of the Upper Airways (ISCOANA), a task force of the International Rhinologic Society (IRS) and serves as a member of the guidelines committee of the German Academy of Otorhinolaryngology.
Success Stories
Join The Success Story of medEctoin®:
License Our Creams Under Your Brand
Your logo could soon be featured on these products – and all in just 8 months. Learn more about claims and applications by clicking on the product of your choice.
